News - Abzena

Filter by year

Filter by topic

Release of first GMP drug substance for an ABZENA Inside product manufactured by Abzena

Cambridge, UK, 8 August 2018 – Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has completed the GMP drug substance manufacture of an ABZENA Inside product that was originally humanised utilising Abzena’s Composite Human Antibody platform™. The product is a novel therapeutic […] Read more

Abzena signs protein engineering agreement with NYU Langone Health

Cambridge, UK, 30 July 2018 – Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has entered into a master service agreement with one of America’s leading academic medical centres, NYU Langone Health (New York, US). The agreement, for protein engineering and drug […] Read more

Abzena and Telix sign strategic manufacturing and bioconjugation agreement

Cambridge, UK and Melbourne, Australia, 2 July 2018 – Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has signed GMP manufacturing and bioconjugation agreements with Telix Pharmaceuticals Limited (‘Telix’). The agreements have a combined value of $5.9 million and these projects are […] Read more

Funding update: Seeking to monetise royalty-bearing ABZENA Inside products

Cambridge, UK, 14 June 2018 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Company’, and together with its subsidiaries, the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, provides an update on its fundraising activities. At the time of the recent full-year results announcement on 4 […] Read more

Full year results: a year of transition – revenue growth driven by investment programme

Cambridge, UK, 4 June 2018 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, has published its full year results for the year to 31 March 2018. Corporate summary FY18 was a year of transition; ambitious growth targets set […] Read more

Notice of full year results

Cambridge, UK, 29 May 2018 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, will publish its full-year results for the year to 31 March 2018 on Monday, 4 June 2018. A presentation for analysts will be held at 09:30 […] Read more

Abzena hosts first Biopharmaceutical Discovery and Development Symposium and open day at Cambridge, UK site

Cambridge, UK, 26 April 2018 – Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, is today hosting its first Biopharmaceutical Discovery and Development Symposium and open day, showcasing its new facility at the Babraham Research Campus in Cambridge, UK. The Symposium […] Read more

Pre-Close Period Trading Update FY2018

Cambridge, UK, 16 April 2018 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, today announces its unaudited pre-close update for the year ended 31 March 2018 (‘FY2018’). Following a stronger second half to the year, the Group expects to […] Read more

Facility Remodelling Completed for Abzena’s New Antibody-Drug Conjugate GMP Manufacturing Suite

CAMBRIDGE, England & BRISTOL, PA, USA, Abzena plc, the life sciences group providing services and technologies to enable the design, development and manufacture of biopharmaceutical products, has announced the completion of the facility remodelling for its new antibody-drug conjugate (ADC) GMP manufacturing suite at its Bristol, Pennsylvania site. The facility is being equipped with state-of-the-art […] Read more

Abzena strengthens specialized bioassay offering through access agreement with major cell line depository

Cambridge, UK, 13 March 2018 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), the life sciences group providing services and technologies to enable the discovery, design, development and manufacture of biopharmaceutical products, has signed an agreement to access a major cell line depository. The agreement with an unnamed institution will allow Abzena access to […] Read more

Interested in our services? Get In Touch